These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 34639059)

  • 1. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment.
    Bolandi N; Derakhshani A; Hemmat N; Baghbanzadeh A; Asadzadeh Z; Afrashteh Nour M; Brunetti O; Bernardini R; Silvestris N; Baradaran B
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
    Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
    Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of B7 family molecules in hematologic malignancy.
    Greaves P; Gribben JG
    Blood; 2013 Jan; 121(5):734-44. PubMed ID: 23223433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
    Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
    [No Abstract]   [Full Text] [Related]  

  • 5. Alternative immune checkpoints in immunoregulatory profile of cancer stem cells.
    Mortezaee K; Majidpoor J
    Heliyon; 2023 Dec; 9(12):e23171. PubMed ID: 38144305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7 family protein glycosylation: Promising novel targets in tumor treatment.
    Xiao L; Guan X; Xiang M; Wang Q; Long Q; Yue C; Chen L; Liu J; Liao C
    Front Immunol; 2022; 13():1088560. PubMed ID: 36561746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New B7 Family Checkpoints in Human Cancers.
    Ni L; Dong C
    Mol Cancer Ther; 2017 Jul; 16(7):1203-1211. PubMed ID: 28679835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Therapeutic Targets of B7 Family in Colorectal Cancer.
    Wang C; Feng H; Cheng X; Liu K; Cai D; Zhao R
    Front Immunol; 2020; 11():681. PubMed ID: 32477326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 12. PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia.
    Zong L; Zhang M; Wang W; Wan X; Yang J; Xiang Y
    Histopathology; 2019 Sep; 75(3):421-430. PubMed ID: 31013360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis.
    Qin X; Sun W; Wang C; Li M; Zhao X; Li C; Zhang H
    Reprod Biol Endocrinol; 2021 Jul; 19(1):114. PubMed ID: 34289871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer.
    Yang J; Tian Z; Gao H; Xiong F; Cao C; Yu J; Shi W; Zhan Q; Yang C
    BMC Cancer; 2022 May; 22(1):584. PubMed ID: 35624419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer.
    Lv C; Han S; Wu B; Liang Z; Li Y; Zhang Y; Lang Q; Zhong C; Fu L; Yu Y; Xu F; Tian Y
    Front Immunol; 2022; 13():984172. PubMed ID: 36159808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7x-from bench to bedside.
    Kaur G; Janakiram M
    ESMO Open; 2019; 4(5):e000554. PubMed ID: 31555486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the B7 family of co-stimulatory molecules: successes and challenges.
    Podojil JR; Miller SD
    BioDrugs; 2013 Feb; 27(1):1-13. PubMed ID: 23329394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review.
    Ahangar NK; Hemmat N; Khalaj-Kondori M; Shadbad MA; Sabaie H; Mokhtarzadeh A; Alizadeh N; Derakhshani A; Baghbanzadeh A; Dolatkhah K; Silvestris N; Baradaran B
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.